Le Lézard
Classified in: Health, Business
Subjects: TRI, CXP

BioClinica Expands Operational Capabilities, Opens New European Offices


NEWTOWN, Pa., June 30, 2015 /PRNewswire/ -- BioClinica®, Inc., the world's leading specialty clinical trial service provider, announced today the opening of new and expanded offices in London and Munich to better serve its growing client base in Europe. The state-of-the-art facilities will offer an array of clinical trial services including medical imaging, site training and support, and eClinical product lines to meet the growing need of European drug and medical device sponsors. BioClinica's clients include top pharmaceutical, biotechnology, and medical device companies as well as CRO partnerships in Europe and across the globe.

BioClinica, Inc.

"Our new offices will serve as important hubs that enable efficient delivery of tailored resources to our European and Global clients" said John Hubbard, BioClinica's CEO. "Infrastructure investments and the recruitment of local scientific, medical, and regulatory expertise highlights BioClinica's firm commitment to supporting clinical drug development in Europe".

Together, the London and Munich offices offer a combined space of 1,400 square meters to support clinical trial services across key therapeutic areas. With a focus on medical imaging, the European offices will showcase an advanced image analysis center for BioClinica's extensive network of European radiologists and imaging specialists. "Our expansion will provide the resources needed for regional scientific and medical experts to assemble and deliver high quality central review of imaging data for multisite trials in Europe" said David Herron, BioClinica's President of Medical Imaging, Cardiovascular Safety, and Molecular Markers.

BioClinica is holding an open house event for the London office on July 2nd for clients, sponsors, and partners in which members of the Executive Leadership team and representatives from BioClinica's Medical Imaging and Biomarker, Site network and patient recruitment, and eClinical business segments will be on hand to discuss and demonstrate clinical trial capabilities.

BioClinica is poised to expand its eClinical division in Europe, delivering products and showcasing technologies that facilitate efficient drug development in the region. "Our newly expanded offices provide an interactive environment for training and demonstration of our eClinical technology suite" said Mukhtar Ahmed, President of eClinical Solutions.

The London office is located at 72 Hammersmith Road and the Munich office is located at Landsberger Strasse 290. BioClinica has plans for an Open House at the Munich office later this summer.

For more information on BioClinica's specialized clinical trial services, visit www.bioclinica.com.

About BioClinica, Inc.
BioClinica accelerates the development of new medical therapies by delivering expertise and technologies that enhance clinical research, worldwide. Our industry-leading medical imaging services, cardiac safety, and enterprise eClinical platform bring a new level of quality and efficiency to every phase of clinical development. Our experience spans three decades and includes thousands of studies in all therapeutic areas, from design and management, through submission and post-approval. BioClinica serves more than 400 pharmaceutical, biotechnology, and device companies ? including the top 20 ? through a network of offices in the U.S., Europe, and Asia.

Logo - http://photos.prnewswire.com/prnh/20130403/PH87647LOGO

SOURCE BioClinica, Inc.


These press releases may also interest you

at 06:08
The following statement has been provided on behalf of all of the shareholders of Thames Water:  "Shareholders and Thames Water have been working with the regulator Ofwat for over a year on how to address the complex challenges facing the business....

at 06:08
Aesthetic Management Partners LLC, a manufacturer of skin-based solutions and a provider of energy-based devices announces its collaboration with Croma (Croma-Pharma® GmbH), a global player in the minimally invasive aesthetics market and a leading...

at 06:05
Zura Bio Limited ("Zura Bio") a clinical-stage immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today reported full year 2023 financial results and recent business highlights. The Company has also...

at 06:05
REX American Resources Corporation ("REX" or the "Company") , a leading ethanol production company, today announced financial and operational results for the Company's full year and fiscal fourth quarter 2023. REX American Resources' Q4 and full...

at 06:05
Calibre Mining Corp. ("Calibre" or the "Company") is pleased to announce the Company has entered into a key pre-commissioning and commissioning contract with Reliable Controls Corporation of Salt Lake City ("RCC") for the Company's Valentine Gold...

at 06:00
Canada's construction sector experienced a slight contraction in 2023, as growth in the non-residential sector was offset by a moderate decline in activity in the residential sector. Despite this trend, the industry continues to perform at an...



News published on and distributed by: